141 related articles for article (PubMed ID: 27689094)
1. Preparation of Thermosensitive Gel for Controlled Release of Levofloxacin and Their Application in the Treatment of Multidrug-Resistant Bacteria.
Alves DA; Machado D; Melo A; Pereira RF; Severino P; de Hollanda LM; Araújo DR; Lancellotti M
Biomed Res Int; 2016; 2016():9702129. PubMed ID: 27689094
[TBL] [Abstract][Full Text] [Related]
2. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
Flynn CM; Johnson DM; Jones RN
J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
[TBL] [Abstract][Full Text] [Related]
7. Comparative study on resistant pattern of clinical isolates against levofloxacin and cefepime.
Nasiri MI; Naqvi SB; Zaidi AA; Saeed R; Raza G
Pak J Pharm Sci; 2013 Mar; 26(2):415-9. PubMed ID: 23455216
[TBL] [Abstract][Full Text] [Related]
8. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Scoper SV
Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
[TBL] [Abstract][Full Text] [Related]
9. [In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010].
Yamaguchi K; Ohno A; Ishii Y; Tateda K; Iwata M;
Jpn J Antibiot; 2012 Jun; 65(3):181-206. PubMed ID: 23173294
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin, a second-generation fluoroquinolone.
North DS; Fish DN; Redington JJ
Pharmacotherapy; 1998; 18(5):915-35. PubMed ID: 9758306
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.
Timmers GJ; Dijstelbloem Y; Simoons-Smit AM; van Winkelhoff AJ; Touw DJ; Vandenbroucke-Grauls CM; Huijgens PC
Bone Marrow Transplant; 2004 Apr; 33(8):847-53. PubMed ID: 14755314
[TBL] [Abstract][Full Text] [Related]
14. [Surveillance of in vitro susceptibilities to levofloxacin and various antibacterial agents for 11,762 clinical isolates obtained from 69 centers in 2013].
Yamaguchi K; Tateda K; Ohno A; Ishii Y; Murakami H
Jpn J Antibiot; 2016 Feb; 69(1):1-25. PubMed ID: 27290827
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
[TBL] [Abstract][Full Text] [Related]
16. [In vitro susceptibilites to levofloxacin and various antibacterial agents of 11,475 clinical isolates obtained from 52 centers in 2002].
Yamaguchi K; Ohno A; Kashitani F; Iwata M; Kanda M; Tsujio Y; Shimoyama N; Okujima H; Ito M; Kawaguchi H; Chiba H; Akizawa K; Katayama Y; Sugimoto K; Tashiro H; Kaimori M; Suwabe A; Obata R; Sugiyama T; Toyoshima S; Kato J; Kaku M; Kanemitsu K; Kunishima H; Okada J; Tazawa Y; Igari J; Oguri T; Watanabe K; Kobayashi Y; Uchida H; Totsuka K; Kon S; Nakamura K; Matsuda K; Hayashi I; Shiotani J; Shiotani J; Kanno H; Itoh A; Sumitomo M; Uchida T; Kawabata A; Oiwa C; Iwata M; Horii T; Ishigo S; Yoshimura T; Ichiyama S; Wada Y; Kimura S; Maesaki S; Itoh K; Noda Y; Yamashita T; Yamaguchi I; Kageyama F; Shaku E; Baba H; Inuzuka K; Okabe H; Tatewaki K; Moro K; Aihara M; Matsushima T; Niki Y; Kuw Abara M; Ikawa S; Tanaka M; Hinoda Y; Sugiura T; Kamioka M; Ono J; Takata T; Makino H; Murase M; Miyamoto H; Aizawa H; Honda J; Takii M; Nagasawa Z; Aoki Y; Hamazaki N; Tsutsui T; Nakagawa K; Iwata M; Hiramatsu K; Saikawa T; Yamane N; Kimoto H; Kotani T; Kageoka T; Hongo T; Masuda J; Miyanohara H; Tsujimura M; Yasujima M; Hayashi I
Jpn J Antibiot; 2005 Feb; 58(1):17-44. PubMed ID: 15849869
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens.
Lanzafame A; Bonfiglio G; Santini L; Mattina R
Chemotherapy; 2005 Mar; 51(1):44-50. PubMed ID: 15767745
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of two multidrug-resistant Klebsiella species in an Indian teaching hospital and adjoining community.
Rath S; Padhy RN
J Infect Public Health; 2014; 7(6):496-507. PubMed ID: 24996691
[TBL] [Abstract][Full Text] [Related]
19. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility testing of newer quinolones against gram positive and gram negative clinical isolates.
Iffat W; Shoaib MH; Muhammad IN; Rehana ; Tasleem S; Gauhar S
Pak J Pharm Sci; 2010 Jul; 23(3):245-9. PubMed ID: 20566434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
